FindTrial
Sign In

The Effects of Craving and Abstinence From Cigarettes on Brain Metabolism in Smokers

The Effects of Craving and Abstinence From Cigarettes on Brain Metabolism in Smokers.

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00267813
Enrollment
24
Registered
2005-12-21
Start date
2004-07-31
Completion date
2007-10-31
Last updated
2008-05-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nicotine Dependence

Keywords

craving, nicotine, imaging, FDG, PET, smoking, Bupropion

Brief summary

Craving and withdrawal from smoking cigarettes are major factors for relapse. We investigated craving for cigarettes in smokers undergoing pharmacological treatment with Bupropion (Zyban). We compare cue-induced reactivity to smoking videos in smokers who were successfully treated with Bupropion to smokers who are still smoking. We measured the brain's metabolic activity in response to smoking and neutral cues in Positron Emission Tomography using FDG.

Detailed description

Craving and withdrawal from smoking cigarettes are major factors for relapse. We investigated craving for cigarettes in smokers undergoing pharmacological treatment with Bupropion (Zyban)for 2 months. We compare cue-induced reactivity to smoking videos in smokers who were successfully treated with Bupropion to smokers who are still smoking. We measured the brain's metabolic activity after exposure to videotapes showing smoking and neutral scenes in Positron Emission Tomography using FDG. There were 2 scanning sessions, one with a smoking videotape and one with a neutral video separated by a week. So far we have compared the brain's metabolic activity in 6 abstinent smokers and 6 still smokers.

Interventions

DRUGBupropion (Zyban)

1 tablet a day increasing to 2 tablets a day after a week

Sponsors

Tel-Aviv Sourasky Medical Center
Lead SponsorOTHER_GOV

Study design

Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
20 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

* Cigarette smokers (over 1 pack a day) * Age 20-65, male-females

Exclusion criteria

* Dependence on other substances * Psychiatric diagnosis * Neurological disorder * Obesity * Young persons * Pregnant women

Design outcomes

Primary

MeasureTime frame
Brain metabolic activity (FDG) in response to craving and neutral cues.30-40 minutes

Secondary

MeasureTime frame
Subjective ratings of craving10 minutes

Countries

Israel

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026